肝胆相照论坛

标题: CaroGen推出研究乙肝治疗性疫苗技术 [打印本页]

作者: StephenW    时间: 2015-8-18 13:09     标题: CaroGen推出研究乙肝治疗性疫苗技术

CaroGen unveils research for hepatitis B therapeutic vaccine technology
Published on Monday, Aug 17, 2015 @ 6:32pm by Vaccine News Daily Reports

CaroGen Corporation, an emerging vaccine company, recently announced that it has electronically published information about its research for therapeutic vaccine technology, specifically for the hepatitis B virus.

An estimated 240 million people around the world suffer from chronic hepatitis B virus infections. Approximately 600,000 people die from these infections every year.

The article is titled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.” It was published online in the August issue of the Journal of Virology.

“The publication of this work is a major milestone for CaroGen, as it provides a peer-reviewed report of our proof-of-concept HBV vaccine studies to date,” Dr. Bijan Almassian, CEO of CaroGen, said.

The research was conducted at Yale University by Dr. John Rose and Dr. Michael Robek. They used their virus-like vesicle (VLV) platform technology, which was developed by Dr. John Rose, who is a virologist at Yale University and a professor of pathology at the Yale School of Medicine. The technology receive licensure from CaroGen in 2012.

“There is a clear need for new therapies for chronically infected individuals,” Dr. Michael Robek, senior author of the research and faculty member in the department of pathology at Yale University, said. “With the virus-like vesicle technology and hepatitis B vaccine candidates under development, we are looking to deliver the needed balance of safety combined with induction of functional immune responses.”


作者: StephenW    时间: 2015-8-18 13:09

CaroGen推出研究乙肝治疗性疫苗技术
周一公布,2015年8月17日@下午6点32由疫苗新闻日报报道

CaroGen公司,新兴公司的疫苗,最近宣布,它已经公布的电子对其研究治疗性疫苗技术的信息,专门为乙肝病毒。

世界各地估计有2.4亿人患有慢性乙肝病毒感染。大约有60万人从这些感染每年死于。

这篇文章的题目是“病毒样囊泡基础的治疗疫苗载体慢性乙型肝炎病毒感染。”这是在病毒学杂志八月号在网上公布。

“这部作品的出版是CaroGen一个重要的里程碑,因为它提供了概念证明我们的乙肝疫苗研究数据的同行评审报告,”赞Almassian博士,CaroGen的首席执行官说。

这项研究是在耶鲁大学博士约翰·罗斯和迈克尔Robek博士进行。他们用自己的病毒样囊泡(VLV)平台技术,这是由约翰·博士玫瑰,谁是病理的医学耶鲁大学教授的病毒学家在耶鲁大学和发展。该技术从CaroGen在2012年获得执照。

“有一个明确的需要为慢性感染者的新疗法,”博士迈克尔·Robek,研究和教学人员在病理耶鲁大学新闻系的资深作者,说。 “随着正在开发的病毒样囊泡技术和乙肝疫苗的候选人,我们正在寻找能够提供安全性结合感应功能的免疫反应所需要的平衡。”
作者: tonychant    时间: 2015-8-18 13:16

就是不说疗效




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5